SHR-A1403ADC is an antibody–drug conjugate composed of an antibody against c-Met (C-mesenchymal epithelial transformation factor, a hepatocyte growth factor receptor) and a toxin-inhibiting proliferation, migration, and invasion of tumor cells [80]. The gene discussed is MET; the disease is neoplasm.